TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03784703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: 40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 Mg Oral Tablet
Description: 10 mg per day rosuvastatin (ROSUVA group, n= 80) for 6 months
Study: NCT03499925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behaviors
Description: Telephone consultation effectiveness and cognitive behaviors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone consultation
Description: Telephone consultation effectiveness and cognitive behaviors
Study: NCT04436159

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Addition of 360 fundoplication after crural closure
Description: A total fundoplication was constructed in which the right and left part of the wrap was brought together in front of, and slightly to the right of the esophagus, and sutured with three interrupted stitches of 2-0 unabsorbable sutures from the GEJ and cranially to attain a length between the top and bottom sutures of at the most 2 cm. At least one wrap suture included the esophageal muscle-wall.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Addition of 180 posterior fundoplication after crural closure
Description: The wrap was pulled dorsally around the distal part of the esophagus and GEJ, which was encircled approximately 180-200 degrees. First, the wrap was anchored with Gore-tex sutures, dorsally to the left crus with 3 sutures and then to the right crus with another 3 sutures.~Finally, the wrap was completed with 3-4 sutures, between the edges of the wrap and the right and left side of the esophageal wall, respectively.
Study: NCT04188340

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Su-Man formula massage oil
Description: bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
Study: NCT02620722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Tourniquet Instrument
Description: Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld Doppler ultrasound
Description: Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
Study: NCT03980431

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FBY PET Examination
Description: A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FBY PET Examination
Description: A single dose of 0.10 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
Study: NCT02000180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Group
Study: NCT03774758

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Health ct-DNA LUNAR assay
Description: Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Health ct-DNA LUNAR assay
Description: Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Health ct-DNA LUNAR assay
Description: Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Health ct-DNA LUNAR assay
Description: Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Health ct-DNA LUNAR assay
Description: Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant Health ct-DNA LUNAR assay
Description: Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
Study: NCT04136366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-2191 (intravitreal methotrexate 0.8%)
Description: ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical care procedure
Description: Standard surgical care performed upon completion of pars plana vitrectomy
Study: NCT01444131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline, Nicotine Patch
Description: active nicotine patches added to varenicline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline and Placebo Patch
Description: placebo nicotine patches added to varenicline.
Study: NCT00265629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF catheter ablation
Description: RF ablation using mesh device
Study: NCT04597229

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Instant multigrain supplement
Description: A twice daily instant multigrain supplementation for 12 weeks
Study: NCT02812173

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic tube ex 2 day
Description: balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: suprapubic tube ex 5 day
Description: balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral catheter ex 5 day
Description: transurethral catheter withdrawal removal on the fifth day after the surgery
Study: NCT04280835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychoeducation that Focused on Social Skill Development
Description: Psychoeducation Program consists of; Preparatory Session, Recognition of Schizophrenia, Evaluating the Treatment of Schizophrenia, Stress and Coping with Stress, Improving Communication Skills, Improving Problem-solving Skills, Improving Interpersonal relationships and social activities and Evaluating Session.The sessions were held in the form of PowerPoint presentations. In the psychoeducation program, lecture, question-answer, homework, sharing experiences, group discussion, repetition, video presentation, summarization, reinforcer, and role-playing techniques were used. The day before each session, patients were phoned and reminded of the time of the session. At the end of each session, the content of the subject is given as hard copy and cookies, tea and coffee were served.
Study: NCT01126086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: otamixaban XRP0673
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: otamixaban XRP0673
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous
Study: NCT04188340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Su-Man formula massage oil
Description: bergamot massage oil:dilute bergamot essential oil(0.5%) with almond oil Su-Man formula massage oil: mixed 4 different essential oil include bergamot, red mandarin, petit grain bigarade, spikenard and diluted with almond oil 5%.
Study: NCT01126086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: otamixaban XRP0673
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous
Study: NCT04544085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: noise management
Description: The intervention mainly includes the following three parts: control of noise source, control of noise transmission and personal protection of noise receiver.(1) control of noise source:equipment maintenance,alarm management,set quiet time,etc.;(2)control of noise transmission:improvement of architectural design;(3)personal protection of noise receiver:providing patients with earmuffs or earplugs.
Study: NCT02551861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT00115648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: Oral NVP daily dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Oral NVP daily dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Oral NVP daily dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZT
Description: Oral AZT daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT
Description: Oral AZT daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP and AZT
Description: Oral single dose NVP plus oral daily AZT during the first weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP
Description: Oral NVP daily to age 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP+AZT
Description: Oral NVP daily plus oral AZT daly to age 14 weeks
Study: NCT04015492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Damoctocog-alfa-pegol (BAY94-9027, Jivi)
Description: Single dose, 50 IU/kg BAY94-9027 (IU: international Units)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Damoctocog-alfa-pegol (BAY94-9027, Jivi)
Description: Single dose, 50 IU/kg BAY94-9027 (IU: international Units)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol (Adynovi)
Description: Single dose, 50 IU/kg Adynovi

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rurioctocog alfa pegol (Adynovi)
Description: Single dose, 50 IU/kg Adynovi
Study: NCT01330784

Intervention type: DRUG
Intervention: hMG-HP
Study: NCT03666624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized care network
Description: The Personalized care network intervention includes exercise training for participant with dementia and behavioral management training for addressing challenges.
Study: NCT00578383

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Field Magnetic Stimulation Device
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
Study: NCT03166059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CaveoVasc® Thrombolysis Protection System
Description: CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
Study: NCT03918161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRE exam
Description: Magnetic Resonance Elastography
Study: NCT03524742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado-Mediterranean Diet
Description: Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control-Group Diet
Description: A low fat-high complex carbohydrate diet, during 3 months.
Study: NCT02718066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000 in combination with nivolumab
Description: Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice.
Study: NCT02037360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator App/Training
Description: This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental App/Training
Description: It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
Study: NCT02302209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT03383887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo before sleep

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAW1033D oral capsule
Description: DAW1033D before sleep
Study: NCT02458534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mcgrath Mac videolaryngoscope
Description: Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-MAC videolaryngoscope
Description: Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: macintosh laryngoscope
Description: Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
Study: NCT02086708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear Wave sonoelastography
Description: Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
Study: NCT04745702

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Meals Rich in Plant Components
Description: Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Low Calorie Balanced Meals
Description: Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
Study: NCT02509390

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
Study: NCT02175537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Microclinic Social Induction Diabetes and Obesity Program
Description: Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
Study: NCT02191423

Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: administered pre-fMRI assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: administered pre-fMRI assessment

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: administered pre-fMRI assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: administered pre-fMRI assessment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic psychotherapy
Study: NCT03623841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task training
Description: Participants in experimental group will do dual-task training via exer-game which combined with treadmill
Study: NCT01435239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The cuff inflation by the resting volume
Description: 80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The cuff inflation by the maximum volume
Description: 80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
Study: NCT00640666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Behavior Change
Description: Multidisciplinary
Study: NCT03327155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)
Description: One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
Study: NCT03604744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.1 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.1 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.1 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.1 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: LSD 0.2 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.2 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.2 mg per os, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: LSD 0.2 mg per os, single dose
Study: NCT02197689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Medication Management Platform for SMS Reminder
Description: The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
Study: NCT00094809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.